StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on MetaVia (MTVA)

Fri, 10 Jul 2026 06:50:46 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $20.00 price target on MetaVia (NASDAQ: MTVA).

The analyst commented: "MetaVia announced that all active patients in both the Part 3a and 3b cohorts have successfully reached the highest target doses of 48 mg and 64 mg. We view the update as modestly positive, but mainly as a titration and execution milestone ahead of the more important 4Q26 topline readout. The key takeaway is that DA-1726 appears able to reach higher exposure levels without an obvious early tolerability ceiling, although this is not the same as completed 64 mg efficacy or

Form 8-K MetaVia Inc. For: Jul 09

Thu, 09 Jul 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260709/26750759.html

Form 8-K MetaVia Inc. For: Jul 09

Thu, 09 Jul 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260709/26750759.html

MetaVia completes dose titration in Phase 1 Part 3 obesity trial

Thu, 09 Jul 2026 08:31:22 -0400

MetaVia Inc. (Nasdaq: MTVA) announced that all active patients enrolled in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for obesity treatment have completed dose titration and are now receiving their highest target doses across both study cohorts.

Part 3 of the Phase 1 program consists of two 16-week titration cohorts. In Part 3A, patients titrated from 16 mg to 48 mg. In Part 3B, patients titrated from 16 mg to 32 mg and then to 64 mg. The trial has a planned enrollment of approximately 40 obese adult subjects, with roughly 20 subjects per cohort, randomized at a

MetaVia completes dose titration in Phase 1 Part 3 obesity trial

Thu, 09 Jul 2026 08:31:22 -0400

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg

Topline Data Remains on Track for Fourth Quarter 2026

CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg

Topline Data Remains on Track for Fourth Quarter 2026

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg

Topline Data Remains on Track for Fourth Quarter 2026

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg

Topline Data Remains on Track for Fourth Quarter 2026

Form 8-K MetaVia Inc. For: Jul 02

Thu, 02 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260702/26727649.html

Form 8-K MetaVia Inc. For: Jul 02

Thu, 02 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260702/26727649.html

Form 424B5 MetaVia Inc.

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727549.html

Form 424B5 MetaVia Inc.

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727549.html

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Fri, 26 Jun 2026 08:35:00 -0400

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24^th & 25^th Life Sciences Virtual Investor Forum are now available for on-demand viewing.

REGISTER AND VIEW PRESENTATIONS HERE

Select companies are accepting 1x1 management meeting requests through June 19^th. Please Schedule 1x1 Meetings here.